Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy.

Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.

Key Stats

• Today's Range: $15.67 to $16.11
• 50-Day Range: $13.95 to $16.42
• 52-Week Range: $7.28 to $16.88
• Volume: 928,327 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $2.08 billion
• P/E Ratio: 7.71
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Moderate Buy

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

Aurinia Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 361st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Aurinia Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Aurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -1.23%

Earnings Growth

Earnings for Aurinia Pharmaceuticals are expected to decrease by -1.23% in the coming year, from $0.81 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurinia Pharmaceuticals is 7.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurinia Pharmaceuticals is 7.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Price to Book Value per Share Ratio

Aurinia Pharmaceuticals has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.80% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.44.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently decreased by 15.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurinia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aurinia Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.82

News Sentiment

Aurinia Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

4 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $7,224,982.00 in company stock, which represents 0.3466% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Aurinia Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,224,982.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

AUPH Stock Analysis - Frequently Asked Questions

How have AUPH shares performed this year?

Aurinia Pharmaceuticals' stock was trading at $15.95 on January 1st, 2026. Since then, AUPH stock has increased by 0.6% and is now trading at $16.04.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, February, 26th. The biotechnology company reported $1.53 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $1.32. The biotechnology company had revenue of $77.11 million for the quarter, compared to analysts' expectations of $74.70 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 27.47% and a net margin of 101.46%.
Read the conference call transcript.

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.26%), Ritholtz Wealth Management (0.24%), Hillsdale Investment Management Inc. (0.16%) and SG Americas Securities LLC (0.14%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AUPH
• CIK: 1600620
• Web: www.auriniapharma.com
• Phone: 250-708-4272
• Fax: 250-744-2498
• Employees: 300
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Aurinia Pharmaceuticals: $17.25
• High Price Target: $21.00
• Low Price Target: $15.00
• Potential Upside/Downside: +7.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.08
• Trailing P/E Ratio: 7.71
• Forward P/E Ratio: 19.80
• P/E Growth: N/A
• Net Income: $287.20 million
• Net Margins: 101.46%
• Pretax Margin: 40.33%
• Return on Equity: 27.47%
• Return on Assets: 19.61%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 5.25
• Quick Ratio: 4.76

Sales & Book Value

• Annual Sales: $283.05 million
• Price / Sales: 7.36
• Cash Flow: $1.03 per share
• Price / Cash Flow: 15.56
• Book Value: $4.41 per share
• Price / Book: 3.64

Miscellaneous

• Outstanding Shares: 129,940,000
• Free Float: 114,086,000
• Market Cap: $2.08 billion
• Optionable: Optionable
• Beta: 1.44